AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00291642
Drug: Levocetirizine drops
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Drops for oral administration~* Concentration: 5 mg/ml~* Route of administration: Oral use
Trial: NCT03410108
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib tablet
Trial: NCT01673295
Drug: RTX infusions
RxNorm normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTX + Standard of Care
Trial: NCT03007693
Drug: JNJ-61393215
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-61393215 for 7 days.
Trial: NCT02697227
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive nicotine patch
Trial: NCT03128866
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00549042
Drug: OROS hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
Trial: NCT04043806
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT00198198
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01081730
Drug: systemic non-biological treatments
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: as prescribed
Trial: NCT00115817
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03467789
Drug: Dietary Vitamin D3 pre-treatment
RxNorm normalized name: vitamin D3
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is \< 31 ng/mL, and 5 days if the D3 level is \> 31 ng/mL
Trial: NCT03467789
Drug: Serum Maintenance Vitamin D3
RxNorm normalized name: vitamin D3
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
Trial: NCT00291642
Drug: Levocetirizine tablets
RxNorm normalized name: levocetirizine Oral Tablet
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Tablets for oral administration~* Concentration: 5 mg~* Route of administration: Oral use
Trial: NCT03822377
Drug: Ticagrelor orodispersible tablets
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
Trial: NCT03822377
Drug: Ticagrelor standard tablets
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
Trial: NCT02611921
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
Trial: NCT00621946
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Escitalopram
Trial: NCT00733564
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracervical injection of 2% Lidocaine to block associated nociception input
Trial: NCT00733564
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
Trial: NCT00733564
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
Trial: NCT00721825
Drug: Neuroaid
RxNorm normalized name: lidocaine hydrochloride Topical Cream [Neuromed]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuroaid capsules, 4 capsules, three times per day, during one month
Trial: NCT02021292
Drug: Macitentan
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan 10 mg, oral tablet, to be taken once daily.
Trial: NCT04501978
Drug: PF-07304814
RxNorm normalized name: PF-07304814
DrugBank: PF-07304814 (DB16514)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
Trial: NCT00102271
Drug: Oxypurinol
RxNorm normalized name: oxypurinol
DrugBank: Oxypurinol (DB05262)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00977977
Drug: Rituximab Infusion
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
Trial: NCT00977977
Drug: Oral Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
Trial: NCT00102271
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01229527
Drug: Meperidine
RxNorm normalized name: Meperidine
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
Trial: NCT00291642
Drug: Cetirizine drops
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Drops for oral administration~* Concentration: 10 mg/ml~* Route of administration: Oral use
Trial: NCT00291642
Drug: Cetirizine tablets
RxNorm normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Tablets for oral administration~* Concentration: 10 mg~* Route of administration: Oral use
Trial: NCT02341729
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: crushed tablets and non-crushed tablets
Trial: NCT00003613
Drug: O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00003613
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT04159805
Drug: TAK-079
RxNorm normalized name: Anti-Cd38 monoclonal antibody TAK-079
DrugBank: Mezagitamab (DB16370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 subcutaneous injection
Trial: NCT04159805
Drug: TAK-079 Placebo
RxNorm normalized name: Anti-Cd38 monoclonal antibody TAK-079
DrugBank: Mezagitamab (DB16370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 placebo-matching subcutaneous injection
Trial: NCT02930837
Drug: alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02828592
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 IV QD x 5 days (Days -6 to -2)
Trial: NCT02828592
Drug: Rabbit ATG
RxNorm normalized name: Rabbit ATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg/day x 3 days (Days -3 to -1)
Trial: NCT03298906
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
Trial: NCT03298906
Drug: Ticlopidine
RxNorm normalized name: Ticlopidine
DrugBank: Ticlopidine (DB00208)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
Trial: NCT02612363
Drug: Dexmedetomidine for sedation
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose
Trial: NCT00273650
Drug: methylcobalamin
RxNorm normalized name: MethylCobalamin
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
Trial: NCT01894256
Drug: Olaparib tablet dosing
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
Trial: NCT00328276
Drug: Sarcosine
RxNorm normalized name: Sarcosine
DrugBank: Sarcosine (DB12519)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03036124
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg or 5 mg tablets given once daily, per oral use.
Trial: NCT01283971
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
Trial: NCT01283971
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40 mg SC every 2 weeks.
Trial: NCT01283971
Drug: placebo to tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo to tocilizumab IV every 4 weeks for 24 weeks.
Trial: NCT01283971
Drug: placebo to adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo to adalimumab SC every 2 weeks for 24 weeks.
Trial: NCT01283971
Drug: folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate at least 5 mg weekly.
Trial: NCT03302871
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT01679613
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: low or medium dose depending on pilot part
Trial: NCT01679613
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: low dose oral administration
Trial: NCT01679613
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00390936
Drug: Brivanib
RxNorm normalized name: Brivanib
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
Trial: NCT00584376
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
Trial: NCT01766323
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
Trial: NCT03151551
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03151551
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT02177435
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01038674
Drug: anti-IL-20
RxNorm normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
Trial: NCT03044093
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group that will get in addition to Misoprostol also Mifepristone
Trial: NCT03044093
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both groups will get think drug
Trial: NCT04079374
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injections
Trial: NCT04079374
Drug: Enbrel
RxNorm normalized name: Enbrel
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injections
Trial: NCT00432575
Drug: surinabant (SR147778)
RxNorm normalized name: Surinabant
DrugBank: Surinabant (DB13070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00588003
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
Trial: NCT00004767
Drug: Sodium Benzoate
RxNorm normalized name: Sodium Benzoate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004767
Drug: Sodium Phenylacetate
RxNorm normalized name: Sodium Phenylacetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004767
Drug: Sodium Phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01378481
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00871455
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
Trial: NCT00247117
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04140487
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04140487
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04140487
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03604289
Drug: Angiotensin-(1-7)
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Trial: NCT03604289
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline will be used as the placebo comparator
Trial: NCT02979613
Drug: TDF
RxNorm normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg tablet administered orally once daily
Trial: NCT04540497
Drug: Inebilizumab
RxNorm normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inebilizumab is a monoclonal antibody that depletes B cells.
Trial: NCT03282799
Drug: etonogestrel implant
RxNorm normalized name: Etonogestrel Implant
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
Trial: NCT01029678
Drug: Cisplatin IV
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
Trial: NCT01029678
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
Trial: NCT02600897
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
Trial: NCT02600897
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
Trial: NCT02600897
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
Trial: NCT02600897
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
Trial: NCT01613807
Drug: Insulin LISPRO
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Humalog® Mix50/50™ \[50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)\], three times daily at mealtime. Dose determined by blood glucose history.
Trial: NCT01802892
Drug: Ronacaleret 100 mg
RxNorm normalized name: Ronacaleret
DrugBank: Ronacaleret (DB05255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
Trial: NCT01802892
Drug: Ronacaleret 400 mg
RxNorm normalized name: Ronacaleret
DrugBank: Ronacaleret (DB05255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
Trial: NCT01802892
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
Trial: NCT01136746
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
Trial: NCT01565200
Drug: T-DM1
RxNorm normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3.6 mg/kg iv every 3 weeks
Trial: NCT02264418
Drug: ODM 203
RxNorm normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODM 203